BR112016010409A8 - composto, composição farmacêutica, combinação, e, uso de um composto e de uma combinação - Google Patents
composto, composição farmacêutica, combinação, e, uso de um composto e de uma combinação Download PDFInfo
- Publication number
- BR112016010409A8 BR112016010409A8 BR112016010409A BR112016010409A BR112016010409A8 BR 112016010409 A8 BR112016010409 A8 BR 112016010409A8 BR 112016010409 A BR112016010409 A BR 112016010409A BR 112016010409 A BR112016010409 A BR 112016010409A BR 112016010409 A8 BR112016010409 A8 BR 112016010409A8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- combination
- pharmaceutical composition
- compositions
- combinations
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1320021.7A GB201320021D0 (en) | 2013-11-13 | 2013-11-13 | Novel Compounds |
| PCT/EP2014/074222 WO2015071235A1 (en) | 2013-11-13 | 2014-11-11 | Hydrobromide salt ofn-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016010409A8 true BR112016010409A8 (pt) | 2020-04-22 |
Family
ID=49818555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016010409A BR112016010409A8 (pt) | 2013-11-13 | 2014-11-11 | composto, composição farmacêutica, combinação, e, uso de um composto e de uma combinação |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9809540B2 (https=) |
| EP (1) | EP3068763B1 (https=) |
| JP (1) | JP6401265B2 (https=) |
| KR (1) | KR20160083950A (https=) |
| CN (1) | CN105683162A (https=) |
| AU (1) | AU2014350334B2 (https=) |
| BR (1) | BR112016010409A8 (https=) |
| CA (1) | CA2929907A1 (https=) |
| CY (1) | CY1121581T1 (https=) |
| DK (1) | DK3068763T3 (https=) |
| ES (1) | ES2714721T3 (https=) |
| GB (1) | GB201320021D0 (https=) |
| HR (1) | HRP20190449T1 (https=) |
| HU (1) | HUE041873T2 (https=) |
| LT (1) | LT3068763T (https=) |
| ME (1) | ME03328B (https=) |
| PL (1) | PL3068763T3 (https=) |
| PT (1) | PT3068763T (https=) |
| RS (1) | RS58382B1 (https=) |
| RU (1) | RU2685408C1 (https=) |
| SI (1) | SI3068763T1 (https=) |
| SM (1) | SMT201900156T1 (https=) |
| TR (1) | TR201902981T4 (https=) |
| WO (1) | WO2015071235A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170100385A1 (en) * | 2014-05-12 | 2017-04-13 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
| BR112018011138A2 (pt) * | 2015-11-30 | 2018-11-21 | Glaxosmithkline Intellectual Property (No. | formulações para administração intravenosa |
| WO2018073248A1 (en) | 2016-10-17 | 2018-04-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Prognosis of demyelinating diseases patients and treatment thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2009992T3 (pl) * | 2006-04-21 | 2012-11-30 | Glaxosmithkline Llc | Antagoniści receptora IL-8 |
-
2013
- 2013-11-13 GB GBGB1320021.7A patent/GB201320021D0/en not_active Ceased
-
2014
- 2014-11-11 PL PL14799988T patent/PL3068763T3/pl unknown
- 2014-11-11 EP EP14799988.2A patent/EP3068763B1/en active Active
- 2014-11-11 ES ES14799988T patent/ES2714721T3/es active Active
- 2014-11-11 ME MEP-2019-47A patent/ME03328B/me unknown
- 2014-11-11 CA CA2929907A patent/CA2929907A1/en not_active Abandoned
- 2014-11-11 HR HRP20190449TT patent/HRP20190449T1/hr unknown
- 2014-11-11 WO PCT/EP2014/074222 patent/WO2015071235A1/en not_active Ceased
- 2014-11-11 US US15/034,583 patent/US9809540B2/en not_active Expired - Fee Related
- 2014-11-11 TR TR2019/02981T patent/TR201902981T4/tr unknown
- 2014-11-11 DK DK14799988.2T patent/DK3068763T3/en active
- 2014-11-11 AU AU2014350334A patent/AU2014350334B2/en not_active Ceased
- 2014-11-11 RU RU2016116955A patent/RU2685408C1/ru not_active IP Right Cessation
- 2014-11-11 PT PT14799988T patent/PT3068763T/pt unknown
- 2014-11-11 SM SM20190156T patent/SMT201900156T1/it unknown
- 2014-11-11 SI SI201431125T patent/SI3068763T1/sl unknown
- 2014-11-11 HU HUE14799988A patent/HUE041873T2/hu unknown
- 2014-11-11 CN CN201480061455.2A patent/CN105683162A/zh active Pending
- 2014-11-11 BR BR112016010409A patent/BR112016010409A8/pt not_active IP Right Cessation
- 2014-11-11 LT LTEP14799988.2T patent/LT3068763T/lt unknown
- 2014-11-11 JP JP2016529894A patent/JP6401265B2/ja not_active Expired - Fee Related
- 2014-11-11 KR KR1020167015530A patent/KR20160083950A/ko not_active Withdrawn
- 2014-11-11 RS RS20190230A patent/RS58382B1/sr unknown
-
2017
- 2017-10-05 US US15/725,429 patent/US20180079722A1/en not_active Abandoned
-
2018
- 2018-12-13 US US16/218,602 patent/US10604485B2/en not_active Expired - Fee Related
-
2019
- 2019-02-26 CY CY20191100237T patent/CY1121581T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR201902981T4 (tr) | 2019-03-21 |
| US20180079722A1 (en) | 2018-03-22 |
| RU2685408C1 (ru) | 2019-04-18 |
| RS58382B1 (sr) | 2019-04-30 |
| RU2016116955A (ru) | 2017-12-19 |
| EP3068763A1 (en) | 2016-09-21 |
| LT3068763T (lt) | 2019-03-12 |
| AU2014350334B2 (en) | 2017-08-10 |
| PT3068763T (pt) | 2019-03-20 |
| HRP20190449T1 (hr) | 2019-04-19 |
| CY1121581T1 (el) | 2020-05-29 |
| JP2016537344A (ja) | 2016-12-01 |
| US20190112269A1 (en) | 2019-04-18 |
| GB201320021D0 (en) | 2013-12-25 |
| CN105683162A (zh) | 2016-06-15 |
| US9809540B2 (en) | 2017-11-07 |
| HUE041873T2 (hu) | 2019-05-28 |
| EP3068763B1 (en) | 2018-12-19 |
| KR20160083950A (ko) | 2016-07-12 |
| SI3068763T1 (sl) | 2019-04-30 |
| ME03328B (me) | 2019-10-20 |
| US10604485B2 (en) | 2020-03-31 |
| CA2929907A1 (en) | 2015-05-21 |
| DK3068763T3 (en) | 2019-03-18 |
| ES2714721T3 (es) | 2019-05-29 |
| PL3068763T3 (pl) | 2019-05-31 |
| WO2015071235A1 (en) | 2015-05-21 |
| SMT201900156T1 (it) | 2019-05-10 |
| JP6401265B2 (ja) | 2018-10-10 |
| AU2014350334A1 (en) | 2016-06-02 |
| US20160264525A1 (en) | 2016-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120703T1 (el) | Ετεροκυκλικες ενωσεις και χρησεις αυτων | |
| MX2018013490A (es) | Derivados aromaticos de sulfonamida. | |
| DOP2015000245A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| CU20140081A7 (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| EA201690598A1 (ru) | Аминогетероарил бензамиды в качестве ингибиторов киназы | |
| EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
| BR112015022782A2 (pt) | composto, composição farmacêutica, combinação, e, uso de um composto | |
| CL2018001510A1 (es) | Composición farmacéutica que comprende un potente inhibidor de urat1 | |
| BR112014029706A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
| BR112015007310A2 (pt) | compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica | |
| BR112017002214A2 (pt) | composto de fórmula (i), composição farmacêutica e usos de um composto | |
| EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
| MX374628B (es) | Formulacion que comprende un agente hipolipidemico. | |
| BR112015022092A2 (pt) | derivado de di-hidropiridazina-3,5-diona | |
| BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) | |
| ECSP15000868A (es) | Derivados de estra1,3,5(10),16tetraeno 3sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| BR112018072755A2 (pt) | composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica | |
| CR20150322A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3 | |
| BR112018002115A2 (pt) | benzamidas aneladas | |
| BR112018001035A2 (pt) | compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| BR112015023878A2 (pt) | composto, composição farmacêutica, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2696 DE 06-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |